Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients

Blood

Volumn 90, Issue 6, 1997, Pages 2465-2470

  San Miguel, J F ^a   Martinez A ^b   Macedo, A ^b   Vidriales, M B ^b   Lopez Berges C ^b   Gonzalez M ^b   Caballero, D ^b   Garcia Marcos M A ^b   Ramos, F ^b   Fernandez Calvo J ^b   Calmuntia, M J ^b   Diaz Mediavilla, J ^b   Orfao, A ^b  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; CYTARABINE; DAUNORUBICIN; IDARUBICIN; RHODAMINE 123;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER SURVIVAL; DIAGNOSTIC ACCURACY; FLOW CYTOMETRY; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; MULTIDRUG RESISTANCE; PREDICTION; PRIORITY JOURNAL; REMISSION;

EID: 1842375675     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v90.6.2465     Document Type: Article

References (30)

1. Beishuizen A, Verhoeven MA, van Wering ER, Hahlen K, Hooijkaas H, van Dongen JJ: Analysis of Ig and T-cell receptor genes in 40 childhood acute lymphoblastic leukemia at diagnosis and subsequent relapse: Implications for the detection of minimal residual disease by polymerase chain reaction analysis. Blood 83:2238, 1994
2. Campana D, Pui CH: Detection of minimal residual disease in acute leukemia: Methodologic advances and clinical significance [see comments]. Blood 85:1416, 1995
3. Orfao A, Ciudad J, Lopez-Berges MC, Lopez A, Vidriales B, Caballero MD, Valverde B, Gonzalez M, San Miguel JF: Acute lymphoblastic leukemia (ALL): Detection of minimal residual disease (MRD) at flow cytometry. Leuk Lymphoma 13:87, 1994 (suppl 1)
4. Brisco MJ, Hughes E, Neoh SH, Sykes PJ, Bradstock K, Enno A, Szer J, McCaul K, Morley AA: Relationship between minimal residual disease and outcome in adult acute lymphoblastic leukemia. Blood 87:5251, 1996
5. San Miguel JF, Gonzalez M, Orfao A: Minimal residual disease in acute myeloid malignancies, in Degos L, Herman F, Linch D, Lowenberg B (eds): Textbook of Malignant Haematology. London, UK, Martin Dunitz (in press)
6. van Dongen JJ, San Miguel JF: Techniques for detection of minimal residual disease in leukaemia patients, in Meet the Expert Sessions of the Second EHA. Oxford, UK, Blackwell Science, 1996, p 39 (abstr)
7. Brisco MJ, Condon J, Hughes E, Neoh SH, Sykes PJ, Seshadri R, Toogood I, Waters K, Tauro G, Ekert H, Morely AA: Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction [see comments]. Lancet 343:196, 1994
8. Lo Coco F, Diverio D, Pandolfi PP, Biondi A, Rossi V, Avvisati G, Rambaldi A, Arcese W, Petti MC, Meloni G, Mandelli F, Grignani F, Masera G, Barbui T, Pellici PG: Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukaemia. Lancet 340:1437, 1992
9. Miyamoto T, Nagafuji K, Akashi K, Harada M, Kyo T, Akashi T, Takenaka K, Mizuno S-i, Gondo H, Okamura T, Dohy H, Niho Y: Persistence of multipotent progenitors expression AML1/ETO transcripts in long-term remission patients with t(8;21) acute myelogenous leukemia. Blood 87:4789, 1996
10. Macedo A, Orfao A, Vidriales MB, Lopez-Berges MC, Valverde B, Gonzalez M, Caballero MD, Ramos F, Martinez M, Fernandez-Calvo J, Martínez A, San Miguel JF: Characterization of aberrant phenotypes in acute myeloblastic leukemia. Ann Hematol 70:189, 1995
11. Reading CL, Estey EH, Huh YO, Claxton DF, Sanchez G, Terstappen LW, O'Brien MC, Baron S, Deisseroth AB: Expression of unusual immunophenotype combinations in acute myelogenous leukemia. Blood 81:3083, 1993
12. van Dongen JJ, Breit TM, Adriaansen HJ, Beishuizen A, Hooijkaas H: Detection of minimal residual disease in acute leukemia by immunological marker analysis and polymerase chain reaction. Leukemia 6:47, 1992 (suppl 1)
13. Coustan-Smith E, Behm FG, Hurwitz CA, Rivera GK, Campana D: N-CAM (CD56) expression by CD34+ malignant myeloblasts has implications for minimal residual disease detection in acute myeloid leukemia. Leukemia 7:853, 1993
14. Macedo A, Orfao A, Gonzalez M, Vidriales MB, Lopez-Berges MC, Martinez A, San Miguel JF: Immunological detection of blast cell subpopulations in acute myeloblastic leukemia at diagnosis: Implications for minimal residual disease studies. Leukemia 9:993, 1995
15. Campana D, Coustan-Smith E, Janossy G: The immunologic detection of minimal residual disease in acute leukemia. Blood 76:163, 1990 (erratum 76:1901, 1990)
16. Adriaansen HJ, Jacobs BC, Kappers-Klunne MC, Hahlen K, Hooijkaas H, van Dongen JJ: Detection of residual disease in AML patients by use of double immunological marker analysis for terminal deoxynucleotidyl transferase and myeloid markers. Leukemia 7:472, 1993
17. Drach J, Drach D, Glassl H, Gattringer C, Huber H: Flow cytometric determination of atypical antigen expression in acute leukemia for the study of minimal residual disease. Cytometry 13:893, 1992
18. Terstappen LW, Safford M, Konemann S, Loken MR, Zurlutter K, Buchner T, Hiddemann W, Wormann B: Flow cytometric characterization of acute myeloid leukemia. Part II. Phenotypic heterogeneity at diagnosis. Leukemia 6:70, 1992
19. Cheson BD, Cassileth PA, Head DR, Schiffer CA, Bennett JM, Bloomfield CD, Brunning R, Gale RP, Grever MR, Keating MJ, Sawitsky A, Stass S, Weinstein H, Woods WG: Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 8:813, 1990
20. Levelt CN, Eichmann K: Streptavidin-tricolor is a reliable marker for nonviable cells subjected to permeabilization or fixation. Cytometry 15:84, 1994
21. Macedo A, Orfao A, Ciudad J, Gonzalez M, Vidriales B, Lopez-Berges MC, Martinez A, Landolfi C, Cañizo C, San Miguel JF: Phenotypic analysis of CD34 subpopulations in normal human bone marrow and its application for the detection of minimal residual disease. Leukemia 9:1896, 1995
22. Macedo A, Orfao A, Martinez A, Vidriales MB, Valverde B, Lopez-Berges MC, San Miguel JF: Immunophenotype of c-kit cells in normal human bone marrow: Implications for the detection of minimal residual disease in AML. Br J Haematol 89:338, 1995
23. Terstappen LW, Mickaels RA, Dost R, Loken MR: Increased light scattering resolution facilitates multidimensional flow cytometry analysis. Cytometry 11:506, 1990
24. Lamy T, Drenou B, Grulois I, Fardel O, Jacquelinet C, Goasguen J, Dauriac C, Amiot L, Bernard M, Fauchet R, Le Prise P-Y: Multi-drug resistance (MDR) activity in acute leukemia determined by rhodamine 123 efflux assay. Leukemia 9:1549, 1995
25. Dixon WJ: Biomedical-Data Package: Statistical Software. Berkeley, CA, University of California, 1983
26. Sievers EL, Lange BJ, Buckley JD, Smith FO, Wells DA, Daigneault-Creech CA, Shults KE, Bernstein ID, Loken MR: Prediction of relapse of pediatric acute myeloid leukemia by use of multidimensional flow cytometry. J Natl Cancer Inst 88:1483, 1996
27. - cases. Blood 86:2329, 1995
28. Ino T, Miyazaki H, Isogai M, Nomura T, Tsuzuki M, Tsuruo T, Ezaki K, Hirano M: Expression of P-glycoprotein in de novo acute myelogenous leukemia at initial diagnosis: Results of molecular and functional assays, and correlation with treatment outcome. Leukemia 8:1492, 1994
29. Paietta E, Andersen J, Racevskis J, Gallagher R, Bennett J, Yunis J, Cassileth P, Wiernik PH: Significantly lower P-glycoprotein expression in acute promyelocytic leukemia than in other types of acute myeloid leukemia: Immunological, molecular and functional analyses. Leukemia 8:968, 1994
30. Ludescher C, Eisterer W, Hilbe W, Gotwald M, Hofmann J, Zabernigg A, Cianfriglia M, Thaler J: Low frequency of activity of P-glycoprotein (P-170) in acute lymphoblastic leukemia compared to acute myeloid leukemia. Leukemia 9:350, 1995